Alumis Inc. (ALMS)

NASDAQ: ALMS · IEX Real-Time Price · USD
12.50
-0.01 (-0.08%)
At close: Jul 19, 2024, 4:00 PM
12.26
-0.24 (-1.92%)
After-hours: Jul 19, 2024, 4:59 PM EDT
-0.08%
Market Cap 704.62M
Revenue (ttm) n/a
Net Income (ttm) -98.11M
Shares Out 56.37M
EPS (ttm) -1.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,931
Open 12.50
Previous Close 12.51
Day's Range 12.29 - 13.00
52-Week Range 10.45 - 13.53
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 15, 2024

About ALMS

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2024
Employees 109
Stock Exchange NASDAQ
Ticker Symbol ALMS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

On Friday, Alumis Inc ALMS priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering.

22 days ago - Benzinga

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Shares of biopharmaceutical firm Alumis opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday.

22 days ago - Reuters

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis set the pricing of its U.S. initial public offering at $16 per share, the lower end of its price range, valuing it at around $902 million.

22 days ago - Reuters

Alumis Announces Pricing of Initial Public Offering

Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering

22 days ago - GlobeNewsWire

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.

26 days ago - Reuters

Alumis eyes $300 million in proceeds in IPO

Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint o...

26 days ago - Market Watch

Alumis, a biotech focused on immune-mediated diseases, files for a $100 million IPO

Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 weeks ago - Renaissance Capital

Alumis IPO Registration Document (S-1)

Alumis has filed to go public with an IPO on the NASDAQ.

6 weeks ago - SEC